Dare Bioscience Closes $15M Public Offering
Ticker: DARE · Form: 8-K · Filed: Jul 19, 2024 · CIK: 1401914
Sentiment: bullish
Topics: financing, public-offering, clinical-development
TL;DR
Dare Bioscience just closed a $15M public offering to fund its clinical programs. Bullish for pipeline progress.
AI Summary
On July 18, 2024, Dare Bioscience, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised approximately $15.0 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. Dare Bioscience plans to use these net proceeds for general corporate purposes, including funding its ongoing clinical development programs and for working capital.
Why It Matters
This capital infusion provides Dare Bioscience with crucial funding to advance its clinical development programs, potentially moving its drug candidates closer to market approval and commercialization.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company's success is still dependent on the clinical trial outcomes and regulatory approvals of its drug candidates.
Key Numbers
- $15.0M — Gross Proceeds (Raised from public offering to fund operations and clinical development.)
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- July 18, 2024 (date) — Date of earliest event reported
- $15.0 million (dollar_amount) — Gross proceeds from public offering
FAQ
What was the total amount of gross proceeds raised in the public offering?
The company raised approximately $15.0 million in gross proceeds.
When did Dare Bioscience announce the closing of its public offering?
The earliest event reported was on July 18, 2024.
What is the primary intended use of the net proceeds from this offering?
The net proceeds are intended for general corporate purposes, including funding ongoing clinical development programs and for working capital.
What is the company's principal executive office address?
The address is 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
What was the previous name of Dare Bioscience, Inc.?
The company was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
Filing Stats: 790 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-07-19 08:05:26
Key Financial Figures
- $1.00 — "Nasdaq") to regain compliance with the $1.00 per share minimum bid price requirement
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 19KB
- 0001493152-24-028443.txt ( ) — 236KB
- dare-20240718.xsd (EX-101.SCH) — 3KB
- dare-20240718_lab.xml (EX-101.LAB) — 33KB
- dare-20240718_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: July 19, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-